News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would be shocked if the CFO did an offering at these levels.
I think partnership or buyout with Madrigal is in the works.
Core Holding!
$SGMT
We are just getting started I pounded the table to load up in the mid 2's low 3's
LFG!
$SGMT
LFG. Happy Friday!
$SGMT
Loaded to the Gills!
Will wait for the buyout at 1-2 Billion by 2027
$SGMT
want one more chunk of shares under $4.00 this week!
$SGMT
Reached 300K shares Long! Blessed
$SGMT
Another 20k at $4.00 added already this morning thank you! bless!
$SGMT
adding more today!
$SMGT
Added 18k end of the day under $4.00 up to 257k shares Largest Holding after today!
$SGMT
Thierry Chauche - New CFO SGMT 2024
Thierry Chauche :
Vice President, Head of Strategic FP&A at Alexion Pharmaceuticals, Inc.
$39 billion
In the largest pharmaceutical deal of the year, British pharmaceutical giant AstraZeneca has acquired American biotech firm and rare diseases specialist Alexion for $39 billion.
The total consideration paid to the Alexion shareholders was approximately $13.3bn in cash and 236,321,411 new AstraZeneca shares (approximately 94% of which will be represented by new AstraZeneca American Depositary Shares (ADSs)).
Provention Bio Announces Appointment of Thierry Chauche as Chief Financial Officer:
Provention Bio in its $2.9 billion acquisition by Sanofi, among other achievements.
Whats even more interesting is that SGMT believes that as the trials continue they will show better efficacy than AKRO which is a IV infusion with a market cap of 2 Billion SGMT drug is three times more effective than MDGL drug hence the https://ir.sagimet.com/news-releases/news-release-details/sagimet-receives-fda-breakthrough-therapy-designation
Another catalyst is Phase 2 MASH in Pediatric look to start Phase 2 in 2025
SGMT drugDenifanstat Combo Data with GLP1 and THR Betas knock it out of the park.
https://sagimet.com/posterspublications/
It Looks like the new CFO came in to negotiate a buyout there are big hitters on the board of Directors including Tim Walbert:
Mr. Walbert has nearly 30 years of biotechnology and industry experience. He joins Sagimet’s board following a 15-year tenure as president, chief executive officer, and chairman of the board at Horizon Therapeutics, which he built from inception to a leading rare disease company. In 2023, Amgen acquired Horizon for $28 billion, and Mr. Walbert currently serves as a senior advisor to Amgen.
Paul Hoelscher
Mr. Hoelscher served as executive vice president and chief financial officer of Horizon Therapeutics from 2014 to 2022, prior to the company’s acquisition by Amgen. Prior to joining Horizon, Mr. Hoelscher held multiple financial executive roles in various consumer products, retail and business services companies, as well as working in the audit practice of KPMG LLP.
The previous CMO of GIlead who just retired from Gilead a few months ago is also on the board:
Merdad Parsey, MD, PhD
Dr. Parsey joined Sagimet Biosciences as president, chief executive officer and board director in September 2010 and stepped down from the role of president and chief executive officer in 2015. He is currently Chief Medical Officer at Gilead Sciences, Inc. Previously, Dr. Parsey held positions at Genentech, Inc., a member of the Roche Group, Sepracor, Regeneron and Merck, Inc. He has worked on multiple development and post-marketing programs from initial human trials to NDA/BLA submissions in respiratory, inflammation, virology, neurology, ophthalmology and gastrointestinal diseases.
Looks like MDGL GILD AMGN NVO LLY could be potential suitors the magnitude of this oral molecule is a next level blockbuster for a variety of big indications>
https://sagimet.com/about/board-of-directors/
https://sagimet.com/about/executives/
AKRO 2 Billion market cap
ETNB 720 Million market cap
SGMT 130 Million market cap with a versatile fat syntheizer molecule that can treat a variety of diseases including a wide array of oncology indications.
Nearly 60 Million shares traded last week A buyout is in the works that why thierry chauche was brought on as the CFO for SGMT this year.
An example of AKRO history:
$SGMT We reached step #3
Akero:
#1 - Sep 13, 2022 Efruxifermin phase 2b results
#2 - Sep 14, 2022 - offering
#3 - Dec 8 2022 - Efruxifermin Granted FDA Breakthrough Therapy Designation
#4 - Mar 29, 2023 - Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program
#5 - May 16, 2023 - one more offering
#6 - Dec 18, 2023 - Phase 3 - first patient dosed.
Second example is ETNB 89 Bio:
$SGMT Similar sequence of steps, but for 89Bio
#1 - Mar 22 2023 - pegozafermin phase 2b results
#2 - Mar 22 2023 - offering
#3 - Sep 21 2023 - FDA has Granted Breakthrough Therapy Designation to pegozafermin
#4 - Dec 04 2023 - Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
#5 - Dec 12 2023 - one more offering
#6 - Mar 12 2024 - phase 3 first patient dozed
In this case either a buyout a partnership should happen sooner than later with catalyst of completion of FDA meeting on Phase 3 design complete and start of Phase 3
Price Target
The average one-year price target for Sagimet Biosciences Inc. is $33.25. The forecasts range from a low of $6.06 to a high of $70.35
When Goldman Lowered their PT on SGMT is when I started accumulating shares!
$SGMT
SGMT under $4
SGMT under $5
that was fun! i love “bar charts as…
…
” i get a lot of good leads from that free website. 
hey dino, looks like we got a runner here, weeeee!!
grabbed a few on the dip. hi all. 
|
Followers
|
4
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
39
|
|
Created
|
01/16/24
|
Type
|
Free
|
| Moderators | |||
AI
